OTCPK:ISCO

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

International Stem Cell Corporation focuses on the development of therapeutic and biomedical products worldwide.


Snowflake Analysis

Imperfect balance sheet with weak fundamentals.


Similar Companies

Share Price & News

How has International Stem Cell's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ISCO's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

0%

ISCO

-1.5%

US Biotechs

3.8%

US Market


1 Year Return

-4.8%

ISCO

22.1%

US Biotechs

9.7%

US Market

Return vs Industry: ISCO underperformed the US Biotechs industry which returned 22.1% over the past year.

Return vs Market: ISCO underperformed the US Market which returned 9.7% over the past year.


Shareholder returns

ISCOIndustryMarket
7 Day0%-1.5%3.8%
30 Day66.7%3.5%11.4%
90 Day37.9%9.0%6.8%
1 Year-4.8%-4.8%23.3%22.1%12.1%9.7%
3 Year-30.4%-30.4%26.1%22.1%36.2%27.2%
5 Year-88.5%-88.5%-5.5%-11.0%63.7%45.4%

Price Volatility Vs. Market

How volatile is International Stem Cell's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is International Stem Cell undervalued compared to its fair value and its price relative to the market?


In this section, we usually try to help investors determine whether International Stem Cell is trading at an attractive price based on the cash flow it is expected to produce in the future. But as International Stem Cell has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of ISCO’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through International Stem Cell regulatory filings here.
  • Explore potentially undervalued companies in the Pharmaceuticals & Biotech industry.

Future Growth

How is International Stem Cell forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

30.0%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if ISCO's forecast earnings growth is above the savings rate (2.2%).

Earnings vs Market: Insufficient data to determine if ISCO's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if ISCO's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if ISCO's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ISCO's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has International Stem Cell performed over the past 5 years?

28.0%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ISCO is currently unprofitable.

Growing Profit Margin: ISCO is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ISCO is unprofitable, but has reduced losses over the past 5 years at a rate of 28% per year.

Accelerating Growth: Unable to compare ISCO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ISCO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.5%).


Return on Equity

High ROE: ISCO has a negative Return on Equity (-302.05%), as it is currently unprofitable.


Next Steps

Financial Health

How is International Stem Cell's financial position?


Financial Position Analysis

Short Term Liabilities: ISCO's short term assets ($3.5M) exceed its short term liabilities ($1.9M).

Long Term Liabilities: ISCO's short term assets ($3.5M) exceed its long term liabilities ($3.3M).


Debt to Equity History and Analysis

Debt Level: ISCO's debt to equity ratio (167.8%) is considered high.

Reducing Debt: Insufficient data to determine if ISCO's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ISCO has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: ISCO has less than a year of cash runway if free cash flow continues to grow at historical rates of 24.6% each year.


Next Steps

Dividend

What is International Stem Cell's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ISCO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ISCO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ISCO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ISCO's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ISCO's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

10.2yrs

Average board tenure


CEO

Andrey Semechkin (59yo)

10.58yrs

Tenure

US$201,208

Compensation

Prof. Dr. Andrey Semechkin, Ph.D., has been the Chief Executive Officer of International Stem Cell Corporation since November 15, 2009. from December 2008 to November 2009 he served in other senior managem ...


CEO Compensation Analysis

Compensation vs Market: Andrey's total compensation ($USD201.21K) is below average for companies of similar size in the US market ($USD571.43K).

Compensation vs Earnings: Andrey's compensation has been consistent with company performance over the past year.


Board Members

NamePositionTenureCompensationOwnership
Andrey Semechkin
Co-Chairman & CEO10.58yrsUS$201.21k56.59% $3.4m
Russell Kern
Executive VP11.67yrsUS$166.32kno data
Paul Maier
Independent Director12.92yrsUS$109.08k0.42% $25.4k
Kenneth Aldrich
Co-Founder & Chairman Emeritus8.25yrsUS$1.32mno data
Donald Wright
Independent Co-Chairmanno dataUS$124.08k0.063% $3.8k
Evan Snyder
Member of Scientific Advisory Boardno datano datano data
Elena Revazova
Member of Scientific Advisory Boardno datano datano data
Hans-Dieter Volk
Member of Scientific Advisory Boardno datano datano data
Matthias von Herrath
Member of Scientific Advisory Boardno datano datano data
Michael Kalichman
Member of Scientific Advisory Boardno datano datano data

10.2yrs

Average Tenure

67yo

Average Age

Experienced Board: ISCO's board of directors are seasoned and experienced ( 10.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

International Stem Cell Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: International Stem Cell Corporation
  • Ticker: ISCO
  • Exchange: OTCPK
  • Founded: 2001
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$6.031m
  • Shares outstanding: 7.54m
  • Website: https://www.internationalstemcell.com

Number of Employees


Location

  • International Stem Cell Corporation
  • 5950 Priestly Drive
  • Carlsbad
  • California
  • 92008
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ISCOOTCPK (Pink Sheets LLC)YesCommon StockUSUSDJan 2007

Biography

International Stem Cell Corporation focuses on the development of therapeutic and biomedical products worldwide. The company’s products are based on human parthenogenetic stem cells, a proprietary type of pluripotent stem cell. It develops various cell types, including neural stem cells for the treatment of Parkinson’s disease and other central nervous system disorders; liver cells to treat various congenital and acquired liver diseases; and islet cells for the treatment of diabetes. The company also develops, manufactures, and markets skincare products and human cell culture products. Its human cell culture products include human skin cells and reagents for the study of skin disease, toxicology, or wound healing; human cells from the heart and blood vessels, and reagents to study cardiovascular disease and cancer; human bronchial and tracheal cell lines for the study of toxicity, cystic fibrosis, asthma, and pathogenesis; and human mammary epithelial cell lines for the study of breast cancer, three dimensional culture, and carcinogen screening. The company’s human cell culture products also comprise adult stem cells and reagents for regenerative medicine; human prostate cells and specialized medium to study prostate disease; human renal and bladder cells and media to study renal and bladder diseases; human corneal cells and media for the study of corneal disease; human female reproductive system cells for the study of cellular physiology; human skeletal muscle cells for the study of biology, diabetes, insulin receptor studies, muscle metabolism, muscle tissue repair, and myotube development; and other cell culture reagents and supplements for the growth, staining, and freezing of human cells. It sells skincare products through a Website and professional channels; and human cell culture products through its sales force, OEM partners, and brand distributors. The company was founded in 2001 and is headquartered in Carlsbad, California. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/06/06 03:48
End of Day Share Price2020/06/05 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.